Published in:
01-12-2020 | Melanoma | Correction
Correction to: Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence
Published in: Annals of Surgical Oncology | Special Issue 3/2020
Login to get accessExcerpt
In the original article, the survival curves are missing in Fig. 1c and d. Following is the corrected Fig. 1.
Fig. 1
Kaplan–Meier curves for recurrence and survival by symptom status at recurrence. a Recurrence-free survival stratified by AJCC stage. b Survival of patients treated with any systemic therapy for metastatic recurrence stratified by symptom status at recurrence [median survival 21.2 (ASDR) vs. 7.6 months (SR); HR 2.16, 95% CI 1.30–3.59; p = 0.003]. c Survival of patients treated with anti-PD1 therapy for metastatic recurrence, stratified by symptom status at recurrence [median not reached (ASDR) vs. 13.6 months (SR); HR 1.99, 95% CI 0.69–5.72; p = 0.2]. d OS from the start of surveillance stratified by symptom status at recurrence [median survival time 39.2 months (ASDR) vs. 23.2 months (SR); HR 1.59, 95% CI 1.10–2.31; p = 0.02]. OS overall survival, HR hazard ratio, CI confidence interval, AJCC American Joint Committee on Cancer, ASDR asymptomatic surveillance-detected recurrence, SR symptomatic recurrence, PD1 programmed death receptor-1
× ![]()
…